82% Increase in Transgenic R&D for Breast Cancer that is Carcinogenesis caused by Li-Fraumeni Syndrome

82% Increase in Transgenic R&D for Breast Cancer that is carcinogenesis caused by Li-Fraumeni syndrome. Hybrid Medical focused on:

Family history and other risk factors for breast Cancer.
Models for predicting breast cancer risk.
Major genes associated with breast cancer
Screening and risk modification for hereditary breast cancer
Psychosocial issues associated with hereditary breast cancer

Among women, breast cancer is the most commonly diagnosed cancer after nonmelanoma skin cancer.

The syndromes most strongly associated with Breast cancers are BRCA1 or BRCA2 mutation syndromes. Breast cancer is also a common feature of Li-Fraumeni syndrome due to P53 mutations.

Breast Cancer research for a cure has a new friend. P53 or mP53. Mutant in transgenic mice has shown promise in the cure for Breast Cancer. Hybrid Medical e-Clinical generated transgenic
mice carrying mutant p53. We cloned the m53 cDNA from a radiation-induced mouse tumor.

The tumors was treated via a potent atelocollagen suppression of the tumors growth. The Result that mp53 activity caused tumors that can be suppressed by subsequent silencing of the mp53.

This is great news because if you get a Genomics Test and discover that you have Brac1 or Brac2one of the major causes of Breast Cancer, the mP53 Mutant can be suppressed and extend Life

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems